[
    [
        {
            "time": "2018-12-03",
            "original_text": "AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA速/VENCLYXTO速 (venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed the Fixed Treatment Course",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Phase 3",
                    "MURANO Trial",
                    "VENCLEXTA",
                    "VENCLYXTO",
                    "venetoclax",
                    "Rituximab",
                    "Relapsed/Refractory Chronic Lymphocytic Leukemia"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA速/VENCLYXTO速 (venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed the Fixed Treatment Course",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-12-03",
            "original_text": "3 Beaten-Down Biotech Stocks to Buy Before the End of 2018",
            "features": {
                "keywords": [
                    "Beaten-Down",
                    "Biotech Stocks",
                    "Buy",
                    "End of 2018"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "3 Beaten-Down Biotech Stocks to Buy Before the End of 2018",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 3,
                "Headline_Structure": 8,
                "Source_Recency": 2
            }
        },
        {
            "time": "2018-12-03",
            "original_text": "Delayed Humira Biosimilar Boosts AbbVie's Fair Value",
            "features": {
                "keywords": [
                    "Delayed",
                    "Humira",
                    "Biosimilar",
                    "Boosts",
                    "AbbVie",
                    "Fair Value"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Delayed Humira Biosimilar Boosts AbbVie's Fair Value",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]